Contrasting of ImmuCell Corporation (ICCC) and Selecta Biosciences Inc. (NASDAQ:SELB)

Both ImmuCell Corporation (NASDAQ:ICCC) and Selecta Biosciences Inc. (NASDAQ:SELB) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ImmuCell Corporation 11.18M 3.87 1.46M -0.28 0.00
Selecta Biosciences Inc. N/A 4746.85 70.23M -3.14 0.00

Table 1 highlights ImmuCell Corporation and Selecta Biosciences Inc.’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 provides the return on equity, return on assets and net margins of the two firms.

Net Margins Return on Equity Return on Assets
ImmuCell Corporation -13.06% -6.3% -4.4%
Selecta Biosciences Inc. 0.00% -220.1% -86.5%

Liquidity

The Current Ratio of ImmuCell Corporation is 3.2 while its Quick Ratio stands at 2.1. The Current Ratio of rival Selecta Biosciences Inc. is 1.6 and its Quick Ratio is has 1.6. ImmuCell Corporation is better equipped to clear short and long-term obligations than Selecta Biosciences Inc.

Institutional & Insider Ownership

The shares of both ImmuCell Corporation and Selecta Biosciences Inc. are owned by institutional investors at 14.2% and 58% respectively. Insiders owned 4.2% of ImmuCell Corporation shares. On the other hand, insiders owned about 22.2% of Selecta Biosciences Inc.’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
ImmuCell Corporation -0.53% -6.54% 9.22% 5.67% -16.09% -15.13%
Selecta Biosciences Inc. -8.96% -5.34% -61.06% -55.4% -44.66% -44.04%

For the past year ImmuCell Corporation has stronger performance than Selecta Biosciences Inc.

Summary

ImmuCell Corporation beats Selecta Biosciences Inc. on 7 of the 9 factors.

ImmuCell Corporation develops, acquires, manufactures, and sells products that enhance animal health and productivity of cows for the dairy and beef industries in the United States and internationally. The company offers First Defense, an orally delivered scours preventive product for calves; Wipe Out Dairy Wipes, which consist of towelettes that are pre-moistened with a Nisin-based formulation to prepare the teat area of a cow in advance of milking; and California Mastitis Test that could be used for bulk tank and individual cow sample monitoring, as well as to determine which quarter of the udder is mastitic. It is also involved in the development of Mast Out, a Nisin-based treatment of subclinical mastitis in lactating dairy cows; and treatments that prevent E. coli K99 and bovine coronavirus, as well as calf scours caused by enteric pathogens. In addition, the company sells various product applications of its First Defense Technology, including a whey protein concentrate for the nutritional and feed supplement markets. ImmuCell Corporation sells its products to distributors and bovine veterinarians, as well as directly to producers. The company was founded in 1982 and is based in Portland, Maine.

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its lead product candidate is SEL-212, which is in phase I/II clinical trials for the treatment of refractory and chronic tophaceous gout. Selecta Biosciences, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts.